<DOC>
	<DOCNO>NCT00897221</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability deferiprone subject Friedreich 's ataxia ( FRDA ) . The secondary objective evaluate long-term efficacy deferiprone treatment FRDA . The tertiary objective evaluate effect deferiprone : 1. cardiac function , 2. quality life , 3. functional status .</brief_summary>
	<brief_title>A Study Investigating Long-term Safety Efficacy Deferiprone Patients With Friedreich 's Ataxia</brief_title>
	<detailed_description>This multi-centre , open-label , non-randomized , single treatment , safety efficacy study . All subject complete LA29-0207 study eligible participation . Participants receive deferiprone oral solution dose ( 20 40 mg/kg/day ) assign LA29-0207 . The duration treatment 52 week .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Subjects complete ApoPharma study LA290207 2 . Female subject childbearing potential must negative pregnancy test . 3 . Male subject must confirm and/or female partner use effective method contraception length trial 30 day follow completion study early termination . 4 . Signed witness write informed consent/assent , obtain prior first study intervention , well ability adhere study restriction , appointment evaluation schedule . 1 . Serum Ferritin Hemoglobin ( Hb ) level reference range age sexmatched control . 2 . Unable complete T25FW AND score &gt; 5 minute 9HPT . Subjects complete T25FW score â‰¤ 5 minute 9HPT allow enrol ) . 3 . Doubling score 9HPT T25FW compare study baseline result LA290207 . 4 . History evidence neutropenia/agranulocytosis define confirm absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L thrombocytopenia define platelet count &lt; 150 x 109/L . 5 . Occurrence SAEs AEs LA290207 study , opinion investigator cause patient 's participation extension study inappropriate . 6 . Unable comply requirement protocol . 7 . Pregnant , breastfeed plan become pregnant study period . 8 . QTc interval &gt; 450ms . 9 . Have antioxidant prior start study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Friedreich 's ataxia</keyword>
</DOC>